Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Taysha Gene Therapies's price to book ratio was 3.6× on Nov 11, 2026, against 5.9× a year earlier. Over the last 5 years it ranged from 1.5× to 67.3×, with a median of 4.1×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.6× | −3.3 |
| 2025 | Dec 31, 2025 | 6.9× | +2.9 |
| 2024 | Dec 31, 2024 | 4.0× | −47.6 |
| 2023 | Apr 28, 2023 | 51.6× | +42.9 |
| 2022 | Dec 30, 2022 | 8.7× | +5.5 |
| 2021 | Dec 31, 2021 | 3.2× | −0.6 |
| 2020 | Dec 31, 2020 | 3.7× | – |
See a number that looks wrong?